442-P Characterizing human Vδ1+ and Vδ2+ γδ T cells for tumor immunotherapy development

• Andreas Behren,
• Simone Ostrouska,
• Kok Fei Chan,
• Tianming Li,
• Andrew Hammet,
• Marc Rigau,
• Adam P Uldrich

Affiliations

Andreas Behren

2Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australia

Simone Ostrouska

2Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australia

Kok Fei Chan

1Olivia Newton-John Cancer Research Institute, Heidelberg, Australia

Tianming Li

2Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australia

Andrew Hammet

3CSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC, Australia

Marc Rigau

4Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia

Adam P Uldrich

4Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia